BEMPEGALDESLEUKIN for Transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 26 adverse event reports in the FDA FAERS database where BEMPEGALDESLEUKIN was used for Transitional cell carcinoma.
Most Reported Side Effects for BEMPEGALDESLEUKIN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Acute kidney injury | 9 | 5.2% | 1 | 8 |
| Cerebrovascular accident | 9 | 5.2% | 1 | 9 |
| Hypotension | 9 | 5.2% | 0 | 9 |
| Atrial fibrillation | 7 | 4.0% | 0 | 6 |
| Pyrexia | 7 | 4.0% | 1 | 7 |
| Malignant neoplasm progression | 6 | 3.5% | 4 | 5 |
| Eosinophilia | 5 | 2.9% | 0 | 5 |
| Pulmonary embolism | 5 | 2.9% | 2 | 5 |
Other Indications for BEMPEGALDESLEUKIN
Renal cell carcinoma (45)
Malignant melanoma (30)
Non-small cell lung cancer (13)
Metastatic renal cell carcinoma (6)
Sarcoma (6)
Metastatic malignant melanoma (5)
Triple negative breast cancer (5)
Other Drugs Used for Transitional cell carcinoma
PEMBROLIZUMAB (1,951)
ENFORTUMAB VEDOTIN-EJFV (1,179)
GEMCITABINE (825)
ATEZOLIZUMAB (788)
CISPLATIN (672)
ENFORTUMAB VEDOTIN (649)
NIVOLUMAB (595)
AVELUMAB (554)
CARBOPLATIN (493)
GEMCITABINE\GEMCITABINE (255)